Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab in moderate to severe palmoplantar pustular psoriasis (Phase IIa)
2007-003922-70Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efalizumab in Palmoplantar Pustular Psoriasis (PPPP) and pustular psoriasis, sponsored by Technische Universität Dresden. Primary endpoints: Efficacy of efalizumab in palmoplantar pustular psoriasis and Safety of efalizumab in palmoplantar pustular psoriasis. Started Aug 2007; status: terminated.
02
Drugs
efalizumab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)pustular psoriasis
Beyond the preview
Go deeper on 2007-003922-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003922-70.